2'-Deoxy-2'-Fluorouridine 5'-(Dihydrogen Phosphate) | 50270-97-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: 2'-Deoxy-2'-Fluorouridine 5'-(Dihydrogen Phosphate)
• 英文别名: [(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 50270-97-8
• 化学式: C₉H₁₂FN₂O₈P
• 分子量: 326.17
• InChiKey: RTGGYPQTXNSBPD-XVFCMESISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  146
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• Compositions and methods for inhibiting expression of Nav1.8 gene
  申请人：Sah Dinah

  公开号：US20070105806A1

  公开（公告）日：2007-05-10

  The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.

  该发明涉及一种双链核糖核酸(dsRNA)，用于抑制Nav1.8基因(Nav1.8基因)的表达，包括具有核苷酸序列的反义链，其长度小于25个核苷酸，并且与Nav1.8基因的至少一部分基本互补。该发明还涉及包括dsRNA和药用可接受载体的药物组合物；使用该药物组合物治疗由Nav1.8基因表达引起的疾病的方法；以及在细胞中抑制Nav1.8基因表达的方法。
• Compositions and methods for inhibiting expression of huntingtin gene
  申请人：Sah Wen-Yee Dinah

  公开号：US20070099860A1

  公开（公告）日：2007-05-03

  The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.

  该发明涉及一种双链核糖核酸(dsRNA)，用于抑制Huntingtin基因(HD基因)的表达，包括具有核苷酸序列的反义链，其长度小于25个核苷酸，并且与HD基因的至少一部分基本互补。该发明还涉及包括dsRNA和药用载体的药物组合物；使用该药物组合物治疗由HD基因的表达或其突变形式引起的疾病的方法；以及在细胞中抑制huntingtin基因表达的方法。
• COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE
  申请人：Bumcrot David

  公开号：US20070281899A1

  公开（公告）日：2007-12-06

  The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.

  该发明涉及一种双链核糖核酸（dsRNA），用于抑制Eg5基因（Eg5基因）的表达，包括具有核苷酸序列的反义链，其长度不超过30个核苷酸，通常为19-25个核苷酸，并且与Eg5基因的至少一部分基本互补。该发明还涉及一种含有dsRNA和药用载体的药物组合物；使用该药物组合物治疗由Eg5表达和Eg5基因表达引起的疾病的方法；以及在细胞中抑制Eg5基因表达的方法。
• BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN
  申请人：Hoerr Ingmar

  公开号：US20100047261A1

  公开（公告）日：2010-02-25

  The present application describes a base-modified RNA and the use thereof for increasing the expression of a protein and for the preparation of a pharmaceutical composition, especially a vaccine, for the treatment of tumours and cancer diseases, heart and circulatory diseases, infectious diseases, autoimmune diseases or monogenetic diseases, for example in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the base-modified RNA, and an in vivo method.

  本申请描述了一种基础修饰的RNA及其用于增加蛋白质表达和制备药物组合物的用途，特别是用于治疗肿瘤和癌症、心脏和循环系统疾病、传染病、自身免疫性疾病或单基因遗传病，例如基因治疗。本发明还描述了一种体外转录方法、使用基础修饰RNA增加蛋白质表达的体外方法以及一种体内方法。
• Nuclease resistant double-stranded ribonucleic acid
  申请人：Vornlocher Hans-Peter

  公开号：US20060094678A1

  公开（公告）日：2006-05-04

  This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.

  本发明涉及改性的双链寡核糖核酸(dsRNA)，其在细胞和生物液中具有改善的稳定性，以及制备和鉴定具有改善稳定性的dsRNA的方法，以及使用dsRNA抑制目标基因的表达或功能。